BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 28, 2018
View Archived Issues
Atridia begins phase I study of SHR-0410 in healthy volunteers
Read More
New phase I trial studies GD2-specific CAR and IL-15 expressing NKTs in neuroblastoma
Read More
Bionomics initiates phase II study of BNC-210 for the treatment of agitation in elderly
Read More
Discovery of novel inhibitor of human NMT for treatment of the common cold
Read More
First patient enrolled in SARA-INT study of Sarconeos in sarcopenia
Read More
Lilly initiates phase II study of LY-3303560 in early symptomatic AD
Read More
Lupin submits MAA to the EMA for etanercept biosimilar
Read More
Fluorescent imaging with a myelin-binding probe shows promise
Read More
PCI Biotech Holding, IMV enter research collaboration
Read More
Janssen Pharmaceutica patents new PDE2A inhibitors
Read More
Oncolytics Biotech and the Keck School of Medicine collaborate to study new Reolysin combination
Read More
Japanese approval for Opdivo with Yervoy in unresectable melanoma
Read More
Roche and Genentech disclose IRAK-4 inhibitors
Read More
Beactica extends master service agreement with Sanofi
Read More
Croma-Pharma identifies H2S-releasing compounds
Read More
Janssen to terminate studies of daratumumab with atezolizumab and JNJ-63723283
Read More
Pfizer's Xeljanz approved for new indication in Japan
Read More
Janssen Pharmaceutica discloses BACE1 and/or BACE2 inhibitors
Read More
Braeburn resubmits CAM-2038 NDA for opioid use disorder to FDA
Read More
Roche presents compounds for HBV infection
Read More
New phase I study evaluates MRX-2843 in patients with advanced or metastatic solid tumors
Read More
MedImmune initiates phase I study of MEDI-2228 in relapsed or refractory multiple myeloma
Read More
Symphogen opens enrollment in phase I study of Sym-023 in advanced solid tumors or lymphomas
Read More
Mepolizumab approved for EGPA in Japan
Read More
Polysialic acid levels tied to prostate cancer aggressiveness
Read More